WuXi Biologics (Cayman) Inc.
2269
Kedudukan dalam Saham
#991
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Harga Saham
$5.74
Modal Pasaran
$23.64B
Perubahan (1 hari)
-8.79%
Perubahan (1 tahun)
24.58%
Negara
CN
Perdagangan WuXi Biologics (Cayman) Inc. (2269)
Kategori
Healthcare
Pendapatan untuk WuXi Biologics (Cayman) Inc. (2269)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini WuXi Biologics (Cayman) Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi WuXi Biologics (Cayman) Inc. dari 2014 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2025 | $1.04B | 56.60% |
| 2024 | $662.33M | 12.33% |
| 2023 | $589.64M | -24.09% |
| 2022 | $776.72M | 23.63% |
| 2021 | $628.25M | 108.78% |
| 2020 | $300.91M | 85.98% |
| 2019 | $161.80M | 50.86% |
| 2018 | $107.25M | 129.77% |
| 2017 | $46.68M | 84.29% |
| 2016 | $25.33M | 151.48% |
| 2015 | $10.07M | 27.28% |
| 2014 | $7.91M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
